Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00966875 · ClinicalTrials.gov registry record · Phase 2
A Study in Patients With Rheumatoid Arthritis
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 448
- Enrollment target
NCT00966875 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 448 participants.
The verdict
NCT00966875, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 448 participants
- Enrollment target
Study Summary
The primary purpose of the study is to help answer the following research questions, and not to provide treatment for Rheumatoid Arthritis (RA): * The safety of LY2439821 and any side effects that might be associated with it. * Whether LY2439821 can help participants with active RA. * How much LY2439821 should be given to participants.
Interventions
- DRUG Placebo
- BIOLOGICAL LY2439821
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 448 participants |
| Start Date | 2009-08 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00966875
The ClinicalTrials.gov registry entry for NCT00966875 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 448 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00966875 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00966875 about?
NCT00966875 is a clinical study titled "A Study in Patients With Rheumatoid Arthritis". The primary purpose of the study is to help answer the following research questions, and not to provide treatment for Rheumatoid Arthritis (RA): * The safety of LY2439821 and any side effects that might be associated with it. * Whether LY2439821 can help participants with active RA. * How much LY24...
What is the current status of trial NCT00966875?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 448 participants. The study started on 2009-08. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00966875?
The interventions under investigation include: Placebo (DRUG), LY2439821 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00966875?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.